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The aim of this work was to review the published data on the pharmacokinetics of cephalosporins in neonates to
provide a critical analysis of the literature as a useful tool for physicians. The bibliographic search was performed
for articles published up to December 3, 2010, using PubMed. In addition, the book Neofax: A Manual of Drugs Used
in Neonatal Care by Young and Mangum was consulted. The cephalosporins are mainly eliminated by the kidneys,
and their elimination rates are reduced at birth. As a consequence, clearance is reduced and t1/2 is more prolonged
in the neonate than in more mature infants. The neonate’s substantial body water content creates a large volume of
distribution (Vd) of cephalosporins, as these drugs are fairly water soluble. Postnatal development is an important
factor in the maturation of the neonate, and as postnatal age proceeds, the clearance of cephalosporins increases.
The maturation of the kidney governs the pharmacokinetics of cephalosporins in the infant. Clearance and t1/2 are
influenced by development, and this must be taken into consideration when planning a cephalosporin dosage
regimen for the neonate.
KEYWORDS: Cephalosporins; Pharmacokinetics; Neonate.
Pacifici GM. Pharmacokinetics of cephalosporins in the neonate: a review. Clinics. 2011;66(7):1267-1274.
Received for publication on December 14, 2010; First review completed on January 21, 2011; Accepted for publication on March 2, 2011
E-mail: pacifici@biomed.unipi.it
Tel.: 39 050-2218721
INTRODUCTION
Cephalosporins are the most common class of antibiotics
used to treat bacterial infection. These drugs have proven to
be safe, clinically effective, and easy to use.
1,2 The
expanded-spectrum cephalosporins (e.g., cefotaxime, cef-
triaxone, and ceftazidime), either alone or in combination
with other antibiotics, are the most common antibiotics used
as initial empiric therapy for treating serious infections.
3
The first generation of cephalosporins has good activity
against Gram-positive bacteria and relatively modest
activity against Gram-negative bacteria. The second genera-
tion of cephalosporins has increased activity against Gram-
negative microorganisms but tends to be much less active
than the third-generation agents. The fourth generation of
cephalosporins is particularly useful for the empirical
treatment of serious infections in hospitalized patients
when Enterobacteriaceae and pseudomonas are potential
etiologies.
4 Cephalosporins are minimally toxic, with the
exception of ceftriaxone, which displaces bilirubin from
albumin
5,6 and precipitates calcium, resulting in serious
adverse effects.
7,8 The aim of this paper was to review the
literature on the kinetics of cephalosporins in the neonate
and provide a critical analysis of the literature as a useful
tool for physicians.
Bibliographic search
The bibliographic search was performed electronically,
using PubMed to find articles published up to December 3,
2010. First, a Medline search was performed with the key
words ‘‘pharmacokinetics of cephalosporins in neonates,"
with the limit of ‘‘human’’. Other Medline searches were
performed with the key words ‘‘pharmacokinetics of ………
in neonates,’’ followed by the names of single cephalospor-
ins. In addition, the book Neofax: A Manual of Drugs Used in
Neonatal Care by Young and Mangum
9 was consulted. The
bibliographic search produced 37 original articles, four
review articles and two book chapters. The publication
years of this material ranged from 1977 to 2010.
RESULTS
The demographic data for the neonates and the
pharmacokinetic parameters of different cephalosporins
are presented in four tables. Information relative to the
first-generation cephalosporin, cefazolin, and the second-
generation cephalosporins, cefoxitin, and cefuroxime, is
provided in Table 1. Table 2 summarizes the results
relative to the third-generation cephalosporins. Table 3
shows the results relative to cefepime, a fourth-generation
cephalosporin, and Table 4 shows the concentrations of
various cephalosporins in the cerebrospinal fluid (CSF)
and serum.
Clearance (Cl) is expressed in different units by different
authors. This makes comparisons between studies difficult.
To overcome this difficulty, Cl was converted into ml/min/
kg. SD cannot be converted; therefore, Cl values are
reported without SDs.
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Cefazolin. The pharmacokinetics of cefazolin (Table 1) in
11 neonates were studied by Deguchi et al.
10 There was
marked interindividual variability in the distribution
volume (Vd). This parameter ranged from 0.21 to 0.37 L/
kg. The unbound fraction of cefazolin in neonatal plasma
ranged from 0.22 to 0.83. The Vd of cefazolin highly
correlated (r=0.936; p,0.001) with the unbound fraction
of this drug.
Young and Mangum
9 suggested administering 25 mg/kg
cefazolin every 8 to 12 h according to the neonate’s
postmenstrual age and postnatal age. When the postmenstr-
ual age is .45 weeks, the interval between doses should be
six hours.
Second-generation cephalosporins
Cefoxitin. Regazzi et al
11 studied the pharmacokinetics
of cefoxitin in 15 neonates. Their reported kinetic
parameters are summarized in Table 1. The half-life (t1/2)
negatively correlated with postnatal age (r=-0.58; p,0.05).
Young and Mangum
9 suggested administering 25 to 33 mg/
kg cefoxitin every 8 to 12 h according to the neonate’s
postmenstrual age and postnatal age. When the post-
menstrual age is .45 weeks, the interval between doses
should be six hours.
Cefuroxime. Renlund and Pettay
12 studied the
pharmacokinetics of cefuroxime in 104 neonates, and their
reported kinetic parameters are summarized in Table 1. The
serum concentration of cefuroxime decreased with body
weight from 25.6¡9.9 mg/ml (,1 kg body weight) to
19.5¡6.8 mg/ml (.4 kg body weight) because of the
increase in GFR with neonatal maturation. t1/2 showed
similar behavior, decreasing from 5.6 h (2.83 kg body
weight) to 4.0 h (3.83 kg body weight). Cefuroxime did
not accumulate over a period of 8 days and was excreted in
the urine by more than 70%.
Third-generation cephalosporins
Cefotaxime. The kinetic parameters of cefotaxime are
summarized in Table 2. Kafetzis et al
13 described treating
infections with cefotaxime in 32 neonates. The pathogens
that sustained the infection were Escherichia coli, Klebsiella
species, Pseudomonas aeruginosa, Serratia marcescens
Staphylococcus aureus, Staphylococcus epidermidis, and
b-hemolytic streptococcus. All of the isolated pathogens
were susceptible to cefotaxime. These authors clustered the
pharmacokinetic parameters of cefotaxime into four groups
according to the neonates’ gestational age and postnatal age.
With neonatal maturation, t1/2 decreased and Cl increased.
For brevity, Table 2 shows the two extremes of the cohort. In
five patients with meningitis who received 50 mg/kg
cefotaxime twice daily, the concentration of the drug was
simultaneously measured in the CSF and serum 1 to 2 h
after cefotaxime administration. The CSF and serum
concentrations (mean¡SD) were 18.2¡7.4 and 38.6¡10.3
mg/ml, respectively. The CSF-to-serum ratio was 45¡0.12%.
McCracken et al
14 compared the kinetic parameters of
cefotaxime in two groups of neonates; the first had an
average body weight of 1,103 g, and the second had an
average body weight of 2,561 g (p,0.0001). Vd and t1/2 were
greater in the former than the latter group, whereas Cl was
greater in the latter group and AUC was not different in the
two groups.
Cefotaxime is converted into desacetyl cefotaxime in the
neonate, and the peak concentration of desacetyl cefotaxime
is about one-tenth of that of cefotaxime.
15-17 The t1/2 of
desacetyl cefotaxime is 9.4 h in very low-body-weight
neonates.
18 After 50 mg/kg cefotaxime, 50 to 60% of the
dose is excreted unchanged in the urine, and approximately
20% is excreted as desacetyl cefotaxime.
18 The renal Cl of
cefotaxime is quantitatively more important than its meta-
bolic Cl. Gouyon et al
15 observed that the t1/2 of cefotaxime
was negatively correlated with gestational age (r=-0.8954;
p,0.01) and body weight (r=-0.8500; p,0.01). In contrast,
Cl was positively correlated with gestational age (r=0.7280;
p,0.02) and body weight (r=0.8667; p,0.02). The AUC of
cefotaxime was negatively correlated with gestational age
(r=-0.7950; p,0.01), but it did not correlate with body
weight.
One recent study examined cefotaxime in neonates under-
going extracorporeal membrane oxygenation (ECMO).
19
Doses of 50 mg/kg of body weight twice a day (postnatal
age ,1 week), 50 mg/kg three times a day (postnatal age 1 to
4 weeks) or 37.5 mg/kg four times a day (postnatal age .4
weeks) were found to provide sufficient periods of supra-
MIC concentrations to give adequate treatment of infants on
ECMO.
Young and Mangum
9 suggested intravenously adminis-
tering 25 to 33 mg/kg of cefotaxime every 8 or 12 h
Table 1 - Demographic data of the studied neonates and pharmacokinetic parameters of first- and second-generation
cephalosporins. Figures are the mean¡SD.
Cefazolin – First-generation cephalosporins
Gestational
age (wk)
Postnatal age
(days)
Body weight
(g)
No. of
cases
Daily dose
(mg/kg)
Cl
(ml/min/kg)
Vd
(L/kg)
t1/2
(h)
Peak conc.
(mg/ml)
Trough conc.
(mg/ml) Reference
35¡3 9.4¡7.4 2,326¡943 11 30 0.80 0.28¡0.05 na na na 10
Cefoxitin and cefuroxime – Second-generation cephalosporins
Drug
Gesta-
tional
age (wk)
Postnatal
age
(days)
Body
weight
(g)
No.
of
cases
Daily
dose
(mg/kg)
Cl
(ml/min/
kg)
Vd
(L/kg)
t1/2
(h)
Peak
conc.
(mg/ml)
Trough
conc.
(mg/ml) Reference
Cefoxitin 36¡4 ,2 months 2,404¡ 599 15 3063 4.5 0.50¡0.21 1.43¡0.53 69.8¡31.9 na 11
Cefuroxime na ,3 weeks ,1,000 .4,000 104 1063 na na 4.6¡0.7
a 24.2¡8.2
b 6.4¡5.6
b 12
na=not available.
aData obtained in 10 neonates.
bData obtained in 5 neonates.
Kinetics of cephalosporins in the neonate
Pacifici GM
CLINICS 2011;66(7):1267-1274
1268Table 2 - Demographic data of the studied neonates and pharmacokinetic parameters of the third-generation
cephalosporins. Figures are the mean¡SD unless otherwise stated.
Cefotaxime – Third-generation cephalosporins
Comment
Gestational
age
(wk)
Postnatal
age
(days)
Body
weight
(g)
No. of
cases
Daily
dose
(mg/kg)
AUC
(mg.h/ml)
Cl
(ml/min/kg)
Vd
(L/kg)
t1/2
(h)
Peak
conc.
(mg/ml)
Trough
conc.
(mg/ml) Reference
Preterm Preterm ,7 na 18 Note A na 1.37
(ml/min)
0.61¡0.05 5.7¡0.8 na na 13
Term Term 7-28
b na 14 na 4.45 (ml/min) 0.69¡0.08 2.0¡0.5 na na
p ___ ___ ___ ___ ___ ___ ,0.05 NS ,0.05 ___ ___
1.1¡0.22 kg
body weight
na 4.0¡1.6 1,103¡216 14 50 400¡56 23.0
(ml/min/
1.73 m
2)
0.51¡0.06 4.6¡1.1 115.9¡38.1 34.4¡12.1 24
2.6¡0.6 kg
body weight
na 3.5¡1.7 2,561¡607 15 50 392¡77 43.9
(ml/min/
1.73 m
2)
0.44¡0.07 3.4¡0.9 132.7¡37.7 38.1¡6.9
p ___ NS ,0.0001 ___ ___ NS ,0.001 ,0.01 ,0.01 na na
Term 37¡3 4.1¡1.7 1,836¡723 10 25x2 373¡206 1.57 0.43¡0.15 3.7¡1.5 171
a 5
a 15
Preterm 28¡2 4.0¡1.6 1,016¡350 18 50 na 1.23 0.46¡0.03 4.4
a 159.0¡11.6 na 18
Preterm ,32 ,7 na 3 25 262¡46 1.08 0.34¡0.07 3.5¡0.4 73.8¡9.6 11.1
a 17
Term .37 $7 na 5 25 177¡25 2.33 0.36¡0.08 2.0¡0.5 68.2¡9.6 22¡1.3
p ___ ___ ___ ___ ___ ,0.001 ,0.005 NS ,0.001 NS ,0.05
Ceftazidime – Third-generation cephalosporins
Comment
Gestational
age
(wk)
Postnatal
age
(days)
Body
weight
(g)
No. of
Cases
Daily
dose
(mg/kg)
AUC
(mg.h/ml)
Cl
(ml/min/
kg)
Vd
(L/kg)
t1/2
(h)
Peak
conc.
(mg/ml)
Trough
conc.
(mg/ml) Reference
Intravenous 35
a 6
a 2,470
a 7 50 na na na 4.7¡1.5 109¡19.9 11.8¡4.1 20
Intramuscular 37
a 8
a 2,860
a 9 50 IM na na na 3.8¡1.1 53.0¡22.4 8.9¡5.6
p ___ ___ ___ ___ ___ ___ ___ ___ ,0.05 ,0.001 ,0.05
Preterm #32 1-22
b 805-4170
b 7 Note B 912¡203 0.98 0.53¡0.12 6.7¡2.6 111¡15 41¡82 1
Preterm 33-37 14 691¡156 1.25 0.51¡0.12 4.9¡1.6 118¡28 31¡9
Controls 31¡3 3 1,579¡597 84 5062 0.68 0.36¡0.09 6.3¡1.7 115¡39 34¡18 23
Term $38 8 619¡151 1.42 0.48¡0.09 4.2¡1.2 102¡18 29¡8
Indomethacin 29¡2 3 1,133¡334 23 5062 0.46 0.36¡0.2 9.4¡3.1 na na
3 days old 29¡1 3 1,154¡201
Weight at
birth
23 2562 0.51 0.36¡0.06 8.7¡2.8 na na 24
10 days old 29¡1 10 0.69 0.29¡0.04 5.0¡0.9 na na
p ___ ___ ___ ___ ___ ,0.05 ,0.005 ,0.005 ___ ___
Once daily 29¡2 3 1,168¡309 13 25 0.46 0.32¡0.06 8.15¡1.2 na 13.1¡4.7 25
Twice daily 29¡2 3 1,141¡400 15 2562 0.41 0.30¡0.06 7.09¡1.7 na 42.0¡13.4
p ___ ___ NS ___ ___ NS NS NS ___ p,0.001
Ceftriaxone – Third-generation cephalosporins
Comment
Gestational
age
(wk)
Postnatal
age
(days)
Body
weight
(g)
No.
of
cases
Daily
dose
(mg/kg)
Cl
(ml/min/kg)
Vd
(L/kg)
t1/2
(h)
Peak
conc.
(mg/ml)
Trough
conc.
(mg/ml) Reference
50 mg/kg 5 term
neonates and
25 infants 6
weeks to 2
years old
na na 15 50 0.85 0.38¡0.13 5.8¡2.6 230¡64 na 29
75 mg/kg na na 15 75 0.93 0.39¡0.06 5.4¡2.1 295¡75 na
Intravenous 32¡4 1-60
b 1880¡860 12 50 0.28 0.33¡0.07 15.4¡5.6 153¡39 54¡22 30
Intramuscular These values refer to the entire population
of 18 cases.
6 50 IM 0.28 0.32¡0.04 15.8¡5.8 120¡37 54¡19
Preterm na 3.2
a 1164
a 10 50 1.0
(ml/min)
0.61¡0.02 7.7¡0.6 145¡18 66¡3.3 31
Preterm na 6.7
a 1176
a 3 50 0.73
(ml/min)
0.53¡0.03 8.4¡1.6 136¡8.9 71¡4.4
Term na 2.8
a 2670
a 9 50 1.8
(mL/min)
0.52¡0.04 7.4¡0.5 159¡9.1 74¡5.4
Preterm na 22.5
a 2112
a 4 50 1.6
(ml/min)
0.50¡0.05 5.2¡0.6 173¡23 67¡12
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ual age is .45 weeks, the interval between doses should be
six hours.
Ceftazidime. The pharmacokinetic parameters of cefta-
zidime are summarized in Table 2. The ceftazidime concen-
tration was measured after intravenous administration to seven
neonates and after intramuscular administration to 9 infants.
20
Ceftazidime concentrations after intravenous injection declined
biexponentially, and the postdistributive phase occurred 30 to
60 min after administration. The peak ceftazidime concen-
tration was 109¡19.9 (intravenously) and 53.0¡22.4 (intra-
muscularly; p,0.05). The t1/2 of ceftazidime was 4.7¡1.5
(intravenously) and 3.8¡1.1 (intramuscularly; NS).
McCracken et al
21 described the pharmacokinetics of
ceftazidime in three groups of neonates with gestational
ages of #32, 33-37, and $38 weeks. Cl increased with
gestational age, whereas t1/2, AUC and the trough concen-
trations decreased with gestational age.
Blumer et al
22 described ceftazidime’s pharmacokinetics
and penetration into CSF in ten children aged 12 to 540 days.
Ceftazidime at 50 mg/kg was intravenously administered
once per day. The t1/2 of ceftazidime was 1.8¡0.8 h, which
was 2- to 4-fold lower than that reported in neonates during
the first week of life (see Table 2). The two youngest children,
aged 12 and 23 days, had a t1/2 of 3.6 and 2.18 h, respectively.
The Cl of ceftazidime varied by more than 300%; such a large
variation makes it inappropriate to report the average Cl, so
the data from Blumer et al
22 are not shown in Table 2. In
contrast, Vd showed little variation and ranged from 0.27 to
0.38 L/kg, with a mean¡SD of 0.34¡0.07 L/kg. The
ceftazidime concentrations in the CSF and serum were
4.7¡2.5 and 145¡30.4 mg/ml, respectively. The CSF-to-
serum concentration of ceftazidime was 3.5¡1.8%. The ratio
of CSF to serum ceftazidime concentration showed a time-
dependent increase, suggesting that ceftazidime was elimi-
nated more slowly from the CSF than from the vascular
compartment. The MIC of the isolated pathogens ranged
from 0.0156 mg/ml (Neisseria meningitidis) to 0.125 mg/ml
(Haemophilus influenzae, Type B).
Prenatal exposure to indomethacin resulted in signifi-
cantly lower GFR and ceftazidime Cl values.
23 The Cl of
ceftazidime was 0.46 ml/min/kg (n=23) in neonates who
were prenatally exposed to indomethacin and 0.68 ml/
min/mg (No=84) in infants who were not exposed to
indomethacin (p,0.05). The Cl of ceftazidime increased
with gestational age (r=0.83; p,0.001), whereas t1/2 showed
an opposite trend (r=-0.54; p,0.001).
23 The positive
relationship between the Cl of ceftazidime and the Cl of
inulin (r=0.73; p,0.001) indicated that glomular filtration
had an important effect on the Cl of ceftazidime. The Cl of
ceftazidime correlated with the reciprocal of the serum
concentration of creatinine (r=0.72; p,0.001), suggesting
that this compound may interfere with the renal Cl of
ceftazidime.
The ceftazidime Cl increased from days 3 to 10 of life
24
(Table 2). Such increases are due to an increase in GFR. The
inulin Cl was 0.72 (day 3) and 0.91 ml/min (day 10; p,0.05).
The Cl of ceftazidime correlated with GFR (r=0.81;
p,0.001). This correlation indicates the important role of
GFR in the clearance of ceftazidime. The Vd of ceftazidime
decreased between days 3 and 10 of life. During the first
week of life, there was a significant decrease in extracellular
water. Ceftazidime is mainly distributed in the extracellular
water component, and a decrease of extracellular water may
cause a decrease in the Vd during this period. Postnatal
exposure to indomethacin prevented the pharmacokinetic
Cefoperazone – Third-generation cephalosporins
Comment
Gestational
age
(wk)
Postnatal
age
(days)
Body
Weight
(g)
No
Cases
Daily
dose
(mg/kg)
Cl
(ml/min/kg)
Vd
(L/kg)
t1/2
(h)
Peak
conc.
(mg/ml)
Trough
conc.
(mg/ml) Reference
50 mg/kg 32-36
b 1.6 1,420-
2,810
b
12 50 0.60 0.12¡0.01 5.5¡1.7 136¡28 na 32
250 mg/kg These values refer to the entire
population of 15 cases.
3 250 0.58 0.11¡0.01 2.8¡1.7 720¡264 na
Preterm
and term
28-42
b 2-6
b 1,300-
3,700
b
10 10062 0.78 0.41¡0.04 6.5¡0.9 352¡75 60¡10 33
Preterm 27-32
b 1-2
b 1,220
a 5 50 na 0.44¡0.04 8.9¡2.1 159¡22 17¡11 34
Preterm 33-36
b 1-2
b 1,896
a 9 50 na 0.48¡0.14 7.6¡3.1 110¡41 14¡17
Term $37 1-2
b 3,068
a 11 50 na 0.45¡0.01 7.2¡2.0 109¡29 13¡9
Ceftizoxime – Third-generation cephalosporins
Comment
Gestational
age
(wk)
Postnatal
age
(days)
Body
weight
(g)
No.
of
cases
Daily
dose
(mg/kg)
Cl
(ml/min/kg)
Vd
(L/kg)
t1/2
(h)
Peak
conc.
(mg/ml)
Trough
conc.
(mg/ml) Reference
See
Note A
36¡3 0.6¡0.4 2600¡1000 19 Note C 0.68¡0.3 0.37¡0.1 7.2¡3.6 na na 36
38¡3 3.4¡1.6 2800¡1000 15 0.94¡0.3 0.46¡0.1 6.3¡2.3 na na
37¡4 16.0¡1.0 2600¡1000 6 1.5¡0.5 0.57¡0.1 4.7¡1.6 na na
na 116¡52 4600¡1100 12 2.4¡1.1 0.44¡0.1 2.4¡0.9 na na
na=not available. NS=not significant. IM=intramuscular.
aMean; the SD was not available;
brange. Note A: The cefotaxime dose was 25 mg/kg and 50 mg/kg in patients with meningitis. Doses were administered every 12 h in neonates younger
than one week of age and every 8 h in patients 1 to 4 weeks of postnatal age. Note B: The ceftazidime dose was 50 mg/kg every 12 h for neonates in the
first week of life and every 8 h for older infants. Note C: Twenty-five patients received 25 mg/kg, and 27 patients received 50 mg/kg.
Table 2 - Cont.
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1270modification seen from days three to ten of life. This may be
explained by renal function’s dependence on postnatal
changes in extracellular water
24 and the GFR impairment
associated with indomethacin use.
Once-daily versus twice-daily administration of ceftazi-
dime was studied by van den Anker et al.
25 After 25 mg/kg
twice daily, the trough concentration of ceftazidime was
42.0¡13.4 mg/ml, which was higher than the target value of
10 mg/ml. After once-daily dosing, the trough concentration
was 13.1¡4.7 mg/ml, higher than the target value of 10 mg/
ml and higher than major neonatal pathogen MIC99 values
such as those for Streptococcus agalactiae and Escherichia
coli
26,27 (MIC99 ,0.25 mg/ml). Therefore, these authors
suggested that once-daily 25 mg/kg ceftazidime is the
appropriate therapeutic schedule for ceftazidime in the
neonate. This administration schedule conflicts with the one
suggested by Young and Mangum.
9 They suggested
administering 30 mg/kg of ceftazidime every 8 or 12 h
according to the postmenstrual and postnatal age. When the
postmenstrual age is $45 weeks, ceftazidime should be
administered every eight hours.
Ceftriaxone. Ceftriaxone is contraindicated in neonates
because it displaces bilirubin from albumin binding sites,
resulting in a higher free bilirubin serum concentration with
subsequent accumulation of bilirubin in the tissues.
5,6 Even
more dangerous is ceftriaxone’s interaction with calcium.
This interaction precipitates calcium, which results in
serious adverse effects.
7,8
Nonetheless, the literature on ceftriaxone was reviewed to
provide a comprehensive study of cephalosporin use. The
kinetic parameters of ceftriaxone are summarized in Table 2.
The MIC90 of ceftriaxone ranged between 0.06 and 2 mg/ml
for Escherichia coli, Klebsiella species, Proteus species,
Enterobacter species, and Staphylococcus aureus, whereas
Enterococci and Listeria monocytogenes are resistant.
28
Ceftriaxone reached CSF concentrations of 5.4 and 6.4 mg/
ml after intravenous doses of 50 and 75 mg/kg, respec-
tively, and the CSF-to-peak serum concentration was 2.2-
2.3%.
29 Sixty percent of ceftriaxone is eliminated by the
kidneys, and Mulhall et al
30 have described the pharmaco-
kinetics of this drug in the neonate (Table 2).
McCracken et al
31 stratified the kinetic parameters of
ceftriaxone based on neonatal body weight. The longest t1/2,
7.7 to 8.4 h, was found in neonates weighing #1,500 g,
compared with 5.2 to 7.4 h in those weighing .1,500 g. The
shortest t1/2 (3.5 and 4.8 h) was found in two neonates aged
45 to 33 days, respectively. Vd ranged between 0.50 and
0.61 l/kg; the smaller value was found in larger and older
infants. Of nine neonates who received multiple ceftriaxone
doses of 50 mg/kg every 12 h, five showed evidence of
drug accumulation in the plasma. The concentrations of
ceftriazone increased from 20 to 208% (mean 82%) at 0.5 h
and from 15 to 165% (mean 53%) at 6 h after dosing. The
ceftriaxone concentration in randomly collected urine
ranged from 113 to 3,350 mg/ml (median 618 mg/ml).
Young and Mangum
9 suggested administering 50 mg/kg
every 24 h. To treat meningitis, they suggested a 100-mg/kg
loading dose and then 80 mg/kg once daily.
Cefoperazone. The kinetic parameters of cefoperazone
are summarized in Table 2. Gestational age correlated with
Cl (r=0.67; p=0.01) and with a constant rate of elimination
32
(Ke; r=0.57; p=0.05), while t1/2 decreased with advancing
gestational age
33 (r=-0.81; p,0.001). Rosenfeld et al
34
studied the pharmacokinetics of cefoperazone (50 mg/kg)
in 25 infants with a postnatal age of 1 to 2 days. The
neonates were divided into three groups according to their
gestational age. These authors repeated the cefoperazone
treatment in 14 neonates aged 5 to 7 days, and the kinetic
parameters were similar to those obtained at a postnatal age
of 1 to 2 days. The percentage of the cefoperazone dose
excreted in the urine on days 1 and 2 after birth was highest
in the most premature patients (55%) but was not
statistically different from that of full-term infants (37%).
In infants 5 to 7 days old, cefoperazone excretion decreased
in the full-term neonates (27%) and was 55% in the most
premature infants (p,0.03). These data suggest that
cefoperazone is partially metabolized and that its rate of
metabolism depends on neonatal maturation. In adults, 69%
of cefoperazone administered orally is eliminated by hepatic
routes.
35
A study based on seven neonates with body weights
ranging from 1,540 to 3,600 g determined that cefoperazone
penetrates the CSF.
34 The cefoperazone concentration (mg/
ml) in the CSF and serum was 5.3¡3.6 and 89¡58,
respectively. The CSF-to-serum ratio was 10.9¡9.6% and
ranged from 1.4 to 31.7%.
Ceftizoxime. The kinetic parameters of ceftizoxime are
summarized in Table 2. The pharmacokinetics of
ceftizoxime were studied in 52 infants whose postnatal
age ranged from 0.1 to 189 days.
36 t1/2 diminished steadily
as the postnatal aged increased, whereas Cl showed the
opposite trend. In this study, Vd remained relatively
constant
37, and ceftizoxime was excreted essentially
unchanged via the kidney.
36
Fourth-generation cephalosporins
Cefepime. The kinetic parameters of cefepime are
summarized in Table 3. The serum creatinine concentration
was negatively correlated (r=-0.79) with cefepime Cl in
neonates.
38 The serum concentration of creatinine was a
strong predictor of cefepim Cl.
38 The relationship between
cefepime Cl and gestational age was not significant. The
maturation of the renal excretory function is an important
dosing determinant for cephalosporins, including cefepime. In
premature infants, renal function is impaired. Because
cefepime is mainly excreted unchanged, the premature and
Table 3 - Demographic data of the neonates and pharmacokinetic parameters of the fourth-generation cephalosporin
cefepime. Figures are the mean¡SD unless otherwise stated.
Gestational
age (wk)
Postnatal
age (days)
Body Weight
(g)
No. of
cases
Daily dose
(mg/kg)
Cl
(ml/min/kg)
Vd
(L/kg)
t1/2
(h)
Peak conc.
(mg/ml)
Trough conc.
(mg/ml) Reference
30¡5.3 14.7¡14.5 1,910¡1,040 54 5062 1.1 0.43¡0.13 4.9¡2.1 89¡27 18¡10 38
na 2 to 6 months na 8 5063 2.7 0.43¡0.1 1.9¡0.5 184¡38 6¡73 9
31¡3 21.8¡14 1,400¡400 31 5062 1.2 0.41¡0.12 4.3¡1.8 120¡38 18¡13 40
na=not available.
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1271term neonates clear cefepime more slowly than more mature
infants. In neonates, the cefepime Cl value was approximately
40% of that of more mature infants, which results in a longer
t1/2 and a higher trough concentration. Vd was greater in
infants with less than 30 weeks of postconceptional life.
38 This
is consistent with the greater total body water content in the
extremely premature neonate.
Reed et al
39 described the pharmacokinetics of cefepime
in 37 infants and children aged between 2 months and 16
years. The data were grouped by age; the youngest patients
ranged between two and six months of age, and the
pharmacokinetic parameters of cefepime in these patients
are reported in Table 3. Ninety percent of cefepime was
recovered in the urine during 24-h urine collection; thus, the
elimination of cefepime is in large part via the kidneys. The
data for cefepime reveal disposition parameters similar to
those of third-generation cephalosporins, including linearity
over a broad dose range (250-2,000 mg), limited disposition
and Cl mainly by the kidneys.
Lima-Rogel et al
40 compared their own results on the
pharmacokinetics of cefepime in neonates with those of
Capparelli et al
38 and Reed et al.
39 The kinetic parameters
of cefepime measured by Lima-Rogel et al
40 and those of
Capparelli et al
38 were obtained in infants with similar
demographic data, and t1/2 and Cl were comparable in
these two studies. Reed et al
39 described the pharmacoki-
netics of cefepime in older infants and children. In this last
study, t1/2 was one-half and Cl was double the values in
the neonates.
Information on the penetration of cephalosporins in the
CSF is limited. Table 4 summarizes the concentrations of
cefotaxime, ceftazidime, ceftriaxone, cefoperazone, and
cefepime in the CSF and serum and the CSF-to-serum ratio.
Information on the penetration in the CSF is available only
for these cephalosporins. A relevant CSF-to-serum ratio was
observed for cefotaxime
13 and it was 45¡12%. Another
relevant penetration rate in the CSF was observed for
cefoperazone,
34 which was 10.9¡9.6%. This figure seems to
be overestimated, as it ranged from 1.4% to 37.1%. The rate
of penetration of cefepime in the CSF was variable. In two
preterm infants, the CSF-to-serum ratio was 30% and 87%,
whereas in 7 term infants, it ranged from 3.6% to 59%, with
a mean¡SD of 16.7¡21.4%. Table 4 shows the data for all
nine neonates.
DISCUSSION
A common feature in the reviewed literature is the
remarkable interindividual variability of the kinetic parameters
of cephalosporins in the neonate. Such variability is due to
renal maturation, as cephalosporins are fairly water soluble
and are mainly eliminated with the urine.
The pharmacokinetic parameters of cephalosporins are
development dependent; the t1/2 of cefotaxime,
13,14 ceftazi-
dime
24-26 and ceftizoxime
37 decrease with increasing gesta-
tional and postnatal age, whereas Cl shows an opposite
trend. With prenatal and postnatal maturation, GFR
increases, and consequently, the Cl of drugs that are mainly
eliminated by kidneys increases.
41,42 Vd is only slightly
influenced by neonatal maturation, although it tends to
decrease with the maturation of the neonate. This has been
observed for cefotaxime.
20,24 Preterm infants have a higher
water content than term infants,
40 and because cephalos-
porins are fairly water soluble, they are distributed at a
larger volume in preterm infants than in term infants.
The hypersensitivity, resistance and toxicology of cepha-
losporins have been studied in adults, but little is known
about these characteristics in the neonate. Cephalosporin
resistance may be related to the drug’s inability to reach its
sites of action, alterations in the penicillin-binding proteins
that are the targets of cephalosporins or hydrolysis of the b-
lactam ring by b-lactamase.
4 The most common side effects
of cephalosporins are hypersensitivity reactions. The reac-
tions appear to be identical to those caused by penicillins
and may be related to the shared b-lactam structure of both
groups of antibiotics. Immediate reactions, such as anaphy-
laxis, bronchospasm, and urticaria, are typically observed.
4
The cephalosporins have been implicated as potentially
nephrotoxic agents, although they are not nearly as toxic to
the kidneys as the aminoglycosides or polymyxins. In
adults, renal tubular necrosis has followed the administra-
tion of cephaloridine in doses greater than 4 g/day.
4
With the exception of cefotaxime
15,16 and cefoperazone,
34
which are partially metabolized, cephalosporins are mostly
eliminated by the renal route, and maturation of the
excretory renal function increases with development. Cl
correlates with gestational age for cefotaxime,
15 cefoper-
azone,
32 and ceftazidime.
23 The Cl of cefotaxime is 2- to 3-
fold higher in term than preterm infants.
13,14 With
increasing Cl, t1/2 clearly decreases. The Cl of ceftazidime
negatively correlates with the reciprocal of serum concen-
tration of creatinine; thus, the serum creatinine concentra-
tion negatively influences the Cl of ceftazidime.
23
Little is known about the AUC, although this parameter
for cefotaxime is similar in preterm and term infants.
14 In
contrast, the AUC for ceftazidime is greater in neonates with
a gestational age #32 weeks than in term infants.
21 This
Table 4 - Cephalosporin concentration in the cerebrospinal fluid (CSF) and serum in neonates. Figures are the
mean¡SD, unless otherwise stated.
Drug
Daily dose
(mg/kg)
Drug concentration
in CSF (mg/ml)
Drug concentration
in serum (mg/ml)
% CSF-to-serum
ratio Reference
Cefotaxime* 5062 18.2¡7.4 38.6¡10.3 45¡12 13
Ceftazidime *
a 50 4.7¡2.5 145¡30.4 3.5¡1.8 22
Ceftriaxone* 75 6.5
b 295¡64 2.2
b 29
Ceftriaxone* 50 5.4
b 230¡64 2.3
b
Cefoperazone * 50 5.3¡3.6 89¡58 10.9¡9.6
c 34
Cefepime * 5062 4.7¡5.3 32.7¡23.1 25.8¡29.8 43
*Infants with meningitis.
aThe infants’ ages ranged from 12 to 540 days.
bMean; SD was not available. Plasma.
cThe CSF-to-serum ratio ranged from 1.4 to 31.7%.
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1272finding is due to the reduced renal excretory function in
preterm infants compared with term infants. In premature
subjects, the Cl of ceftazidime is reduced; therefore, the
ceftazidime serum concentration slowly decreases, and
AUC tends to increase.
Most of the available information about the kinetics of
cephalosporins deals with the third generation of these
antibiotics. A considerable body of information is available
on cefotaxime, ceftazidime, and ceftriaxone.
The Cl of ceftazidime increases between days 3 and 10 of
life.
24 This increase is due to the increase in GFR. The Cl of
ceftazidime is also correlated with GFR (r=0.81; p,0.001).
This correlation indicates the important effect of GFR on
ceftazidime Cl. Intravenous administration of ceftazidime
yields double the peak concentration of intramuscular
administration.
20
Ceftriaxone is active against Escherichia coli, Klebsiella
species, Proteus species, Enterobacter species, and
Staphylococcus aureus.
28 Cefepime is a fourth-generation
cephalosporin and little is known about this drug, as it is the
latest cephalosporin to enter clinical use. Creatinine nega-
tively influences the Cl of cefepime.
39 Cefepime is primarily
excreted unchanged. Preterm infants clear cefepime more
slowly than full-term infants, as the renal excretory function
rate is reduced in preterm subjects. Consequently, cefepime
has a longer t1/2 and a higher trough concentration in the
preterm infant than the term infant.
38
Meningitis can be treated with cephalosporins, so the
penetration of these drugs in the CSF is important.
Information on the concentration of cephalosporins in CSF
is available for cefotaxime, ceftazidime, ceftriaxone, cefo-
perazone, and cefepime. Cefotaxime reaches a considerable
CSF concentration, and the CSF-to-serum concentration
ratio is relevant.
13 Only one study is available on the
penetration of cefepime in CSF.
43 The concentration of this
drug varies considerably in serum and CSF, and conse-
quently, the CSF-to-serum ratio ranges widely.
The penetration of other cephalosporins into the CSF
should be studied, and we feel that further research is
required to ensure that the doses recommended for treating
sepsis in neonates are entirely evidence-based.
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